Conference Dates: Jan 26, 2010
Washington DC[edit Location]
* What will this new integrated model for pharmacogenetics and drug discovery look like?
* What Rx/Dx partnership incentives can we employ to achieve financial and equivalent goal congruence?
* What is the value of a biomarker that enables a therapy to an equivalent or higher ROI than OSFA?
* What pricing and outcomes models could be utilized to optimize the clinical benefit of targeted therapy and minimize the lag of diagnostic test adoption?
[edit description]Click here to register.[edit ]
Industries[edit]
Fee: $1195[edit ]